AI Governance · AI MedTech / SaMD

AI Governance for AI MedTech / SaMD.

This page focuses on AI governance implications inside regulated work. It shows where AI changes evidence needs while keeping quality, regulatory, data, supplier, and human accountability controls in view.

Source basis: AI/ML-enabled device software, SaMD, and change-control guidanceUse: evidence-readinessBoundary: not legal advice
AI MedTech / SaM TRACE FDA AI/ML SAMD HUBFDA PCCP GUIDANCFDA LIFECYCLE-MAFDA AI-ENABLED D
/ AI governance

AI changes the evidence pattern, not the need for control.

AI MedTech / SaMD
Control 01

Training and validation data

Data provenance, representativeness, and clinical relevance are core evidence.

Control 02

Performance monitoring

Model drift and real-world performance need planned review.

Control 03

Transparency

Users need limits, intended use, updates, and performance information.

Control 04

Cybersecurity and software lifecycle

AI governance sits inside secure, controlled software lifecycle work.

/ Adjacent controls

AI governance must connect to existing regulated systems.

not isolated
Evidence 01

Intended-use and clinical workflow map

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.

Evidence 02

Software function description

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.

Evidence 03

Training/validation data summary

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.

Evidence 04

Performance evaluation report

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.

Evidence 05

Human factors/oversight rationale

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.

Evidence 06

PCCP description

Connect this evidence to QMS, clinical, software, supplier, data, or lifecycle governance where applicable.